Can Moderna turn hantavirus urgency into a credible rare-virus vaccine strategy?
Moderna surged on hantavirus hopes. The real test is whether rare-virus urgency can become a viable mRNA vaccine pathway.
Pharma & Biotech
Moderna surged on hantavirus hopes. The real test is whether rare-virus urgency can become a viable mRNA vaccine pathway.